Idéal Investisseur
Français English
CAC 40 : Market open
8 089,81 pts
+0.14%


Last updated : 29/09/2026 - 12h16
🏠 Home   ➤    Stock news

Adocia stock breaks through its 2.62 € support before a rebound during the session

The Lyon-based biotech specializing in insulin formulations regains ground on Tuesday, after several weeks of marked downward pressure. This rebound occurs in a degraded technical context, with a security that remains far from its moving averages.


Adocia stock breaks through its 2.62 € support before a rebound during the session

A surge that compensates only a fraction of a quarterly decline of 34%

Adocia gains 6.16% during the session at 2.79 €, after closing the previous day at 2.628 €. This rebound places the security among the strongest gains on the CAC All Shares on Tuesday, in a nearly stable Paris market (the CAC 40 advances 0.21% during the session). Today's increase, however, barely attenuates a quarterly decline of 34.42% and a 62% drop over one year, proportions that make the intraday surge difficult to qualify as a reversal.

The previous session had, moreover, been particularly volatile: the security had broken through its 2.62 € support down to a low of 2.55 €, before recovering above this level to close at 2.628 €. The breaking of the support, even temporarily, illustrates the fragility of the current configuration.

An RSI in extreme oversold at 16, well below all moving averages

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

From a technical indicators perspective, the company presents a highly degraded technical picture. The RSI is at 16, an extreme oversold level rarely reached, which reflects the accumulated selling exhaustion over several weeks. The price at 2.79 € remains well below its three moving averages: the MA20 is at 3.65 € (difference of -23.56%), the MA50 at 3.87 € (-27.91%) and the MA200 at 5.00 € (-44.20%). Such a gap to moving averages signals an uninterrupted underlying downtrend.

The nearest resistance is identified at 4.24 €, a level still more than 50% away from the current price. On the fundamental side, the half-year report of July 23 established the loss at 8.6 M€ in the first half of 2026 and financial visibility until the beginning of the second quarter of 2027, with significant uncertainty about going concern mentioned in the document. This context of tight cash flow remains the main fundamental parameter to monitor for the security.



Sector Pharmacie et biotechnologies › Biotechnologies


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 0 millions d'euros
  • Quarterly revenue: 0 millions d'euros
  • Revenue growth: -95,8 %
  • Net income: -8,6 millions d'euros
Guidance from the release
  • visibilité financière maintenue jusqu'au début du deuxième trimestre 2027 ; incertitude significante sur la continuité d'exploitation
Risks mentioned
  • Consommation de trésorerie de 10,1 M€ au premier semestre 2026
  • Horizon de financement limité au début du deuxième trimestre 2027
  • Chiffre d'affaires semestriel en forte baisse, de 1 031 K€ à 43 K€
Opportunities identified
  • Résultats positifs de Phase 3 de BioChaperone® Lispro en Chine et dépôt d'AMM en préparation
  • Trois études de faisabilité BioChaperone® positives avec de grandes pharmas, deux en discussions avancées
  • AdOral® Sema breveté et libre d'exploitation alors que le semaglutide devient libre de droit en 2026

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours